Phase I trial of gemcitabine and epirubicin in patients with solid malignancies.

被引：0
|
作者：
Mahadevan, D
Dreisbach, L
Williams, D
Pilkington, D
Gebremarium, C
Martin, E
Obregon, Y
Von Hoff, D
机构：
[1] Arizona Canc Ctr, Tucson, AZ USA
[2] Desert Hematol & Oncol, Rancho Mirage, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4190
引用
收藏
页码：360S / 360S
页数：1
相关论文
共 50 条
  • [1] Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies.
    Anderson, S
    Dizon, D
    Sabbatini, P
    Dupont, J
    Pezzulli, S
    Massey, A
    Aghajanian, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 151S - 151S
  • [2] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, Amy Patricia
    Thach-Giao Truong
    Thurn, Kenneth Ted
    Thomas, Scott
    Ryan, Charles J.
    Jahan, Thierry Marie
    DuBois, Steven G.
    Chan, John K.
    Rugo, Hope S.
    Collisson, Eric Andrew
    Raha, Paromita
    Chen, Stephanie
    Reinert, Anne
    Daud, Adil
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Collisson, E. A.
    Reinert, A.
    Daud, A.
    Munster, P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies
    Mahadevan, Daruka
    Dreisbach, Luke
    Kristedja, Timothy
    Williams, Debbie
    Obregon, Yrma
    Kurtin, Sandy
    Von Hoff, Daniel D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (06): : 607 - 611
  • [5] A phase I combination study of irofulven (IROF) and gemcitabine (GEM) in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Gore, L
    Long, M
    Gustafson, D
    Eppers, S
    Basche, M
    Rothenberg, M
    Weems, G
    Shah, A
    Herdrich, L
    Eckhardt, SG
    Berlin, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9120S
  • [6] Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies.
    Westin, Shannon Neville
    Stashi, Erin
    Pal, Navdeep
    Urbauer, Diana L.
    Janku, Filip
    Piha-Paul, Sarina Anne
    Naing, Aung
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Hong, David S.
    Subbiah, Vivek
    Karp, Daniel D.
    Coleman, Robert L.
    Meric-Bernstam, Funda
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Phase I study of RFS 2000 and gemcitabine (Gem) in patients with advanced malignancies.
    Fracasso, PM
    Tan, BR
    Sun, SL
    Revell, SM
    Lenaz, L
    CLINICAL CANCER RESEARCH, 2000, 6 : 4515S - 4515S
  • [8] A Phase I Trial of Irinotecan Alternating With Epirubicin in Patients With Advanced Malignancies
    Goff, Laura W.
    Rothenberg, Mace L.
    Lockhart, A. Craig
    Roth, Bruce J.
    VerMeulen, Wendy L.
    Chan, Emily
    Berlin, Jordan D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (05): : 413 - 416
  • [9] Phase I trial of continuously infused gemcitabine with CPT-11 for refractory hematologic malignancies.
    Rizzieri, DA
    Gockerman, JP
    Decastro, CM
    Lilly, S
    Foster, T
    Adams, D
    Moore, JO
    BLOOD, 2000, 96 (11) : 216B - 216B
  • [10] Phase I trial of SNS-595 in patients with advanced malignancies.
    Advani, R
    Gordon, M
    Hurwitz, H
    Mendelson, D
    Wakelee, H
    Ebbinghaus, S
    Hoch, U
    Silverman, J
    Havrilla, N
    Adelman, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 159S - 159S
12345